|[December 09, 2013]
Research and Markets: Global Victoza (Type 2 Diabetes) Report 2013 - Forecast and Market Analysis to 2022
DUBLIN --(Business Wire)--
Research and Markets (http://www.researchandmarkets.com/research/3svhff/victoza_type_2)
has announced the addition of the "Global
Victoza (Type 2 Diabetes) Report 2013 - Forecast and Market Analysis to
2022" report to their offering.
The type 2 diabetes market is mature and crowded with inexpensive
generics. Despite being marked by a late-stage pipeline filled with
me-too drugs, this market will undergo substantial growth between 2012
and 2022, more than doubling over this period. The main drivers of
growth will be the dramatic increase in disease prevalence and
physicians' efforts to delay disease progression and reduce the costly
burden of diabetic complications through the use of cmbination
therapies and novel branded drugs.
Overview of type 2 diabetes, including epidemiology, etiology,
symptoms, diagnosis, pathology and treatment guidelines as well as an
overview on the competitive landscape.
Detailed information on Victoza including product description, safety
and efficacy profiles as well as a SWOT analysis.
Sales forecast for Victoza for the top ten countries from 2012 to 2022.
Sales information covered for the US, France, Germany, Italy, Spain,
the UK, Japan, Brazil, India and China.
Reasons to buy
Understand and capitalize by identifying products that are most likely
to ensure a robust return
Stay ahead of the competition by understanding the changing
competitive landscape for type 2 diabetes
Effectively plan your M&A and partnership strategies by identifying
drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth
analysis of Victoza performance
Obtain sales forecast for Victoza from 2012-2022 in top ten countries
(the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India
Key Topics Covered:
1 Table of Contents
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Victoza (liraglutide)
For more information visit http://www.researchandmarkets.com/research/3svhff/victoza_type_2
[ Back To Technology News's Homepage ]